Technology Transfer

Knowledge and technology transfer (KTT) encompasses a broad range of activities that support mutually beneficial collaborations between universities, industry and the public sector. In practice, KTT translates into scientific exchange through publications, posters and talks at meetings on one side (see also Events and Education), and in precompetitive or competitive research in collaboration with industry on the other side. More about KTT output data can be found in the dedicated page.

Support to the NCCR TransCure researchers

A KTT committee composed of group leaders and consultants from the private sector offers support in the processes related to IP generation in the identification of the translational potential of the NCCR TransCure projects and in the development of marketable ideas. 

The technology transfer offices of the universities are the primary contact for the practical steps and for the legal advice with regard to patents, spin-off development, contracts and regulation of collaborations, and IP matters in general.

The relevant technology transfer offices for the NCCR TransCure are Unitectra (Universities of Bern, Zürich and Basel), ETH Transfer (ETH Zürich) and pactt (University of Lausanne and CHUV).

NCCR TransCure spin-off Synendos Therapeutics

News: NCCR TransCure spin-off Synendos Therapeutics wins BaseLaunch. In December 2018, the BaseLaunch  accelerator program for healthcare startups has selected four projects among over 100 applications received from Switzerland and Europe to receive non-dilutive funding in a competitive two-phase selection process. Among them was the project by Andrea Chicca and Jürg Gertsch from the IBMM (University of Bern) on the development of selective endocannabinoid reuptake inhibitors (SERIs) for neuropsychiatric disorders. The project was initiated by the NCCR TransCure research project “cellular endocannabinoid transport”. Over the last years, they and their collaborators have successfully identified a new drug target and generated solid IP protection on first and second generation SERIs and their medical uses. Their startup Synendos Therapeutics now aims to bring the lead SERI into a phase I clinical trial and the spin-off company will be incorporated at the Swiss Innovation Park in Allschwil in Basel. BaseLaunch is managed and operated by BaselArea.swiss and provides non-dilutive funding, access to Healthcare Partners and knowledge from highly experienced advisors. BaseLaunch is supported by Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and Roivant Sciences as well as by other public and private partners.

Synendos has recently also won the Venture Kick Stage I.

Pre-seed workshop

The NCCR TransCure has been co-organizing the pre-seed workshop series 2016-2018 in partnership with SwissCompanyMaker and other academic partners. This workshops are meant to help young potential entrepreneurs to test the marketability of very early to early stage high-tech ideas and get valuable input from experts on how to move ahead.

The next SwissCompanyMaker Pre-seed workshop will be announced on this page. 

KTT Activities

NCCR TransCure-Novartis research collaborations

TransCure offers selected PhD students or postdocs the possibility of screening and experimental collaborations with researchers of Novartis Basel. These are an excellent training opportunity, serve to generate better tool compounds for basic research, and help academic PIs and industry partners to profile potential common interests. Moreover, educational events such as specialized courses and networking workshops will be offered in the future (more info will be published in due time on this page).


Prof. Jürg Gertsch
NCCR TransCure Delegate for KTT

University of Bern
Institute of Biochemistry and Molecular Medicine
Bühlstrasse 28
CH-3012 Bern

Tel: +41 (0)31 631 41 24
Email: gertsch(at)ibmm.unibe.ch